medigraphic.com
ISSN 0016-3813 (Print)

2018, Number 5

<< Back Next >>

Gac Med Mex 2018; 154 (5)

Frecuencia y gravedad de la retinopatía del prematuro en una unidad de cuidados intensivos neonatales

García H, González-Cabello H, Soriano-Beltrán CA, Soto-Dávila MA, Vázquez-Lara Y, Hernández-Galván C

Language: Spanish
References: 42
Page: 561-568
PDF size: 302.86 Kb.


ABSTRACT

Introduction: Retinopathy of prematurity (ROP) is a disease where retinal blood vessels do not develop normally and may cause visual damage and blindness. Objective: To determine the frequency and severity of ROP in preterm newborns. Method: A descriptive, comparative study was carried out within the 2009-2013 period. Patients’ general characteristics were recorded, including gestational age and postmenstrual age at the moment of ophthalmologic examination, as well as ROP severity and type of treatment. Results: A total of 326 preterm newborns were included: 47.8 % (n = 156) had ROP; in 21.1 % it was severe (stage ≥ 3). Median gestational age was 28 weeks in preterm newborns with ROP, median birth weight was 1000 g, and median postmenstrual age at ophthalmological examination was 36 weeks. Of the infants with ROP, 71.1 % received treatment: 63.4 % of those who had mild ROP and 100 % of those with severe ROP. Conclusions: ROP frequency was high, higher than that reported in developed countries and similar to that in developing countries. The frequency of severe ROP was also higher. It is necessary for effective programs for the detection and opportune treatment of ROP to be established.


REFERENCES

  1. Flynn J. Retinopathy of prematurity. En: Eichenbaum JW. Treatment of retinopathy of prematurity. EE. UU.: Year Book Medical Publishers; 1990.

  2. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: I. Preliminary report. Am J Opthalmol. 2018;192:xxviii.

  3. Heath P. Pathology of the retinopathy of prematurity: retrolental fibroplasia. Am J Ophthalmol. 1951;34:1249-1259.

  4. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate and high levels of development: Implication for screening programs. Pediatrics. 2005;115(5):e518-e525.

  5. Manual of operations. Release 13.2. EE. UU.: Vermont Oxford Network; 2009.

  6. Kinsey VE, Hemphill FM. Etiology of retrolental fibroplasia and preliminary report of cooperative study of retrolental fibroplasia. Trans Am Acad Ophthalmol Otolaryngol. 1955;59:15-24.

  7. Gibson DL, Sheps SB, Uh SH, Schechter MT, McCormick AQ. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics. 1990;86:405-412.

  8. Kinsey VE. Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol. 1956;56:481-543.

  9. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98:1628-1640.

  10. Bullard SR, Donahue SP, Feman SS, Sinatra RB, Walsh WF. The decreasing incidence and severity of retinopathy of prematurity. J AAPOS 1999;3:46-52.

  11. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116:15-23.

  12. Hoogerwerf A, Schalij-Delfos NE, Van-Schooneveld MJ, Termote JU. Incidence of retinopathy of prematurity over the last decade in the Central Netherlands. Neonatology. 2010;98:137-142.

  13. Quinn GE, Barr C, Bremer D, Fellows R, Gong A, Hoffman R, et al. Changes in course of retinopathy of prematurity from 1986 to 2013: comparison of three studies in the United States. Ophthalmology. 2016; 123:1595-1600.

  14. Gerull R, Brauer V, Bassler D, Laubscher B, Nelle M, Müller B, et al. Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006-2015: a population-based analysis. Arch Dis Child Fetal Neonatal Ed. 2018;103 F337-F342.

  15. Ludwig CA, Chen TA, Hernandez-Boussard T, Moshfeghi AA, Moshfeghi DM. The epidemiology of retinopathy of prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48:553-562.

  16. Park SH, Yum HR, Kim S, Lee YC. Retinopathy of prematurity in Korean infants with birthweight greater than 1500 g. Br J Ophthalmol. 2016; 100:834-838.

  17. Hernández M, Orduna C, Bosch V, Salinas R, Alcaraz JL, Marín JM. Retinopatía del prematuro en la región de Murcia (España). Incidencia y gravedad. Arch Soc Esp Oftalmol. 2008;83:423-428.

  18. Cervantes-Munguía R, Espinosa-López L, Gómez-Contreras P, Hernández- Flores G, Domínguez-Rodríguez J, Bravo-Cuéllar A. Retinopatía del prematuro y estrés oxidativo. An Pediatr (Barc). 2006;64:126-131.

  19. González-Urquidi O, De la-Fuente-Torres M. Incidencia de retinopatía del prematuro en el hospital Dr. Manuel Gea González. Rev Mex Oftalmol. 2004;78:1-4.

  20. Sánchez E, Zapata G, Escamilla M. Retinopatía en el prematuro menor a 1500 gr expuesto a concentraciones altas de oxígeno suplementario. Incidencia en Yucatán. Rev Mex Oftalmol. 2008;82:381-384.

  21. Orozco-Gómez P, Ruiz-Morfin I, Lámbarry-Arroyo A, Morales-Cruz MV. Prevalencia de retinopatía del prematuro. 12 años de detección en el Centro Médico 20 de noviembre. Cir Ciruj. 2006;74:3-9.

  22. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006;117:572-576.

  23. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. The Early Treatment for Retinopathy of Prematurity Study; structural findings at age 2 years. Br J Ophthalmol. 2006;90:1378-1382.

  24. Msall ME, Phelps DL, Hardy RJ, Dobson V, Quinn GE, Summers CG, et al. Educational and social competencies at 8 years in children with threshold retinopathy of prematurity in the CRYO-ROP multicenter study. Pediatrics. 2004;113:790-799.

  25. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991-999.

  26. Chow LC, Wright KW, Sola A; CSMC Oxygen Administration Study Group. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003;111:339-345.

  27. Zimmermann-Carrion J, Fortes-Filho FJB, Tartarella MB, Zin A, Dorneles- Jornada I. Prevalence of retinopathy of prematurity in Latin America. Clin Ophthalmol. 2011;5:1687-1695.

  28. Binkhathlan AA, Almahmoud LA, Saleh MJ, Srungeri S. Retinopathy of prematurity in Saudi Arabia incidence, risk factors, and applicability of current screening criteria. Br J Ophthalmol. 2008;92:167-169.

  29. Hameed B, Shyamanur K, Kotecha S, Manktelow B, Woodruff G, Draper ES, et al. Trends in the incidence of severe retinopathy of prematurity in a geographically defined population over a 10-year period. Pediatrics. 2004;113:1653-1657.

  30. Lad EM, Hernández-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol. 2009;148:451-458.

  31. Vinekar A, Dogra MR, Sangtam T, Narang A, Gupta A. Retinopathy of prematurity in Asian Indian babies weighing greater than 1250 grams at birth: ten year data from a tertiary care center in a developing country. Indian J Ophthalmol. 2007;55:331-336.

  32. Sola A, Chow L, Rogido M. Retinopathy of prematurity and oxygen therapy: A changing relationship. An Pediatr (Barc). 2005;62:48-63.

  33. Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362:1959-1969.

  34. Bedrossian RH, Carmichael P, Ritter JA. Effect of oxygen weaning in retrolental fibroplasia. AMA Arch Ophthalmol. 1954;53:514-518.

  35. Bedrossian RH, Carmichael P, Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. I. Clinical study. II. Further observations on the disease. Am J Ophthalmol. 1954;37:78-86.

  36. Hittner HM, Speer ME, Rudolph AJ, Blifeld C, Chadda P, Holbein ME, et al. Retrolental fibroplasia and vitamin E in the preterm infant —comparison of oral versus intramuscular: oral administration. Pediatrics. 1984;73:238-249.

  37. Gaynon MW, Stevenson DK, Sunshine P, Fleisher BE, Landers MB. Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity. J Perinatol 1997;17:434-438.

  38. Lloyd J, Askie L, Smith J, Tarnow-Mordi W. Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity. Cochrane Database Syst Rev. 2003;2:CD003482.

  39. Tin W, Milligan DW, Pennefather P, Hay E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001;84:106-110.

  40. Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010;125:1483-1492.

  41. Secretaría de Salud. Manejo de la retinopatía del recién nacido prematuro. Lineamiento técnico. México: Secretaría de Salud; 2007.

  42. Zepeda-Romero LC, Gutiérrez-Padilla JA, De la Fuente-Torres MA, Angulo- Castellanos E, Ramos-Padilla E, Quinn GE. Detection and treatment for retinopathy of prematurity in Mexico: need for effective programs. J AAPOS. 2008;12:225-226.




2020     |     www.medigraphic.com